Całość tekstu w miesięczniku „Zdrowie bez Leków“ nr 12/grudzień 2021 r. (54) str. 16–19.

Czy leki działają wystarczająco, by nas uchronić przed chorobami?

Zyski Big Pharmy nadal rosną, a poziom zdrowia publicznego nadal spada. Istnieją strukturalne przyczyny tej rozbieżności, w tym elementy historyczne, finansowe i filozoficzne. Rozwiązując te problemy, możemy wprowadzić nową formę opieki zdrowotnej i lepsze zdrowie dla wszystkich.

Po ponad stu latach rozkwitu medycyny farmaceutycznej nadal nie mamy niezawodnych leków na żadną z chorób niezakaźnych. Po ponad stu latach panowania medycyny farmaceutycznej stan zdrowia publicznego pogarsza się w alarmującym tempie.

Bibliografia

1. Aitken M, Kleinrock M, Nass D. 2016. Outlook for Global Medicines Through 2021: Balancing Cost and Value.
2. WifOR The Economic Footprint of the Pharmaceutical Industry.
3. Lazarou J, Pomeranz B, Corey P. Incidence of adverse drug reactions in hospitalized patients. 1998;279:1200-1205
4. Suh DC, Woodall BS, Shin SK, Hermes-De Santis ER. Clinical and economic impact of adverse drug reactions in hospitalized patients. Ann Pharmacother. 2000 Dec;34(12):1373-9.
5. Starfield B. Is US health really the best in the world? 2000 Jul 26;284(4):483-5.
6. Starfield B. Deficiencies in US medical care. 2000 Nov 1;284(17):2184-5.
7. Weingart SN, McL Wilson R, Gibberd RW, Harrison B. Epidemiology of medical error. West J Med. 2000 Jun;172(6):390-3.
8. https://www.cdc.gov/nchs/data/vsushistorical/vsush_1900_4.pdf
9. Armstrong GL, Conn LA, Pinner RW. Trends in infectious disease mortality in the United States during the 20th century. 1999 Jan 6;281(1):61-6.
10. Department of Commerce and Labor, Bureau of the Census. Mortality Statistics, 1900 to 1904. Washington, DC: US Department of Commerce and Labor, 1906.
11. Hoyert DL, Kochanek KD, Murphy SL. Deaths: final data for 1997. Hyattsville, Maryland: US Department of Health and Human Services, Public Health Service, CDC, National Center for Health Statistics, 1999. (National vital statistics reports, vol 47, no. 19).
12. Vaupel JW, Villavicencio F, Bergeron-Boucher M-P. Demographic perspectives on the rise of longevity.  Natl Acad. Sci. USA 118, e2019536118 (2021).
13. Colchero F, Aburto JM, Archie EA and 38 others. The long lives of primates and the ‘invariant rate of ageing’ hypothesis.Nat Commun 12, Article 3666 (2021).
14. Zuo W, Jiang S, Guo Z, Feldman MW, Tuljapurkar S. Advancing front of old-age human survival.  Natl Acad. Sci. USA 115, 11209–11214 (2018)
15. Gurven M, Kaplan H. Longevity among Among Hunter- Gatherers: A Cross-Cultural Examination. Popn Development Rev (2007);33(2),321-365
16. Clayton P, Rowbotham J. How the mid-Victorians worked, ate and died. Int J Environ Res Public Health. 2009 Mar;6(3):1235-53.
17. Mayor A. The Nessus Shirt in the New World; Smallpox Blankets in History and Legend. (1995). J Am Folklore 108(427), 54-77.
18. What Are We Feeding Our Kids? BBC One, May 2021
19. World Health Statistics 2008.
20. Popkin BM. The nutrition transition in low-income countries: an emerging crisis. Nutr Rev. 1994 Sep;52(9):285-98.
21. Global Panel on Agriculture and Food Systems for Nutrition. Food systems and diets: facing the challenges of the 21st century.
22. Food and Agriculture Organization of the United Nations, International Fund for Agricultural Development, Unicef, World Food Programme, World Health Organization. The state of food security and nutrition in the world 2018.
23. United Nations System Standing Committee on Nutrition. Non-communicable diseases, diets and nutrition
24. Institute for Health Metrics and Evaluation, University of Washington. GBD compare data visualization.
25. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. 2015 Jan 10;385(9963):117-71.
26. Lehtonen Š, Sonninen TM, Wojciechowski S, Goldsteins G, Koistinaho J. Dysfunction of Cellular Proteostasis in Parkinson’s Disease. Front Neurosci. 2019 May 10;13:457.
27. Colla E. Linking the Endoplasmic Reticulum to Parkinson’s Disease and Alpha-Synucleinopathy. Front Neurosci. 2019 May 29;13:560.
28. Bond S, Lopez-Lloreda C, Gannon PJ, Akay-Espinoza C, Jordan-Sciutto KL. The Integrated Stress Response and Phosphorylated Eukaryotic Initiation Factor 2α in Neurodegeneration. J Neuropathol Exp Neurol. 2020 Feb 1;79(2):123-143.
29. Sulzer D, Alcalay RN, Garretti F, Cote L, Kanter E, Agin-Liebes J, Liong C, McMurtrey C, Hildebrand WH, Mao X, Dawson VL, Dawson TM, Oseroff C, Pham J, Sidney J, Dillon MB, Carpenter C, Weiskopf D, Phillips E, Mallal S, Peters B, Frazier A, Lindestam Arlehamn CS, Sette A. T cells from patients with Parkinson’s disease recognize α-synuclein peptides. Nature. 2017 Jun 29;546(7660):656-661.
30. Garretti F, Agalliu D, Lindestam Arlehamn CS, Sette A, Sulzer D. Autoimmunity in Parkinson’s Disease: The Role of α-Synuclein-Specific T Cells. Front Immunol. 2019 Feb 25;10:303.
31. Narayan S, Liew Z, Bronstein JM, Ritz B. Occupational pesticide use and Parkinson’s disease in the Parkinson Environment Gene (PEG) study. Environ Int. 2017 Oct;107:266-273.
32. Parkinson Study Group STEADY-PD III Investigators. Isradipine Versus Placebo in Early Parkinson Disease: A Randomized Trial. Ann Intern Med. 2020 May 5;172(9):591-598. doi: 10.7326/M19-2534.
33. Study of Urate Elevation in Parkinson’s Disease, Phase 3 (SURE-PD3) | National Institute of Neurological Disorders and Stroke (2019) https://www.ninds.nih.gov/Disorders/Clinical-Trials/Study-Urate-Elevation-Parkinsons-Disease-Phase-3-SURE-PD3, Accessed April 02, 2020.
34. Simuni T, Fiske B, Merchant K, Coffey CS, Klingner E, Caspell-Garcia C, Lafontant DE, Matthews H, Wyse RK, Brundin P, Simon DK, Schwarzschild M, Weiner D, Adams J, Venuto C, Dawson TM, Baker L, Kostrzebski M, Ward T, Rafaloff G. Parkinson Study Group NILO-PD Investigators and Collaborators. Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2021 Mar 1;78(3):312-320.
35. Whone AL, Boca M, Luz M, Woolley M, Mooney L, Dharia S, Broadfoot J, Cronin D, Schroers C, Barua NU, Longpre L, Lynn Barclay C, Boiko C, Johnson GA, Christian Fibiger H, Harrison R, Lewis O, Pritchard G, Howell M, Irving C, Johnson D, Kinch S, Marshall C, Lawrence AD, Blinder S, Sossi V, Stoessl AJ, Skinner P, Mohr E, Gill SS (2019) Extended treatment with glial cell line-derived neurotrophic factor in Parkinson’s disease. J Parkinsons Dis9, 301–313.
36. Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, Shcherbinin S, Sparks J, Sims JR, Brys M, Apostolova LG, Salloway SP, Skovronsky DM. Donanemab in Early Alzheimer’s Disease. N Engl J Med. 2021 May 6;384(18):1691-1704.
37. https://www.biospace.com/article/biogen-ditches-parkinson-s-disease-drug-after-phase-ii-study-fails-to-show-benefit/
38. https://www.clinicaltrialsarena.com/analysis/alzheimers-biogen-eli-lilly-amyloid-targeting-therapy-fda-approval/
39. GBD 2016 Neurology Collaborators (2019) Global, regional, and national burden of neurological disorders, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol18, 459–480.
40. Dorsey ER, Sherer T, Okun MS, Bloem BR (2018) The emerging evidence of the Parkinson pandemic. J Parkinsons Dis8, S3–S8.
41. Dorsey ER, Bloem BR (2018) The Parkinson pandemic—a call to action. JAMA Neurol75, 9–10.
42. McFarthing K, Buff S, Rafaloff G, Dominey T, Wyse RK, Stott SRW. Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2020. J Parkinsons Dis. 2020;10(3):757-774.
43. https://clinicaltrials.gov/ct2/show/NCT04829760
44. https://clinicaltrials.gov/ct2/show/NCT04854291
45. https://clinicaltrials.gov/ct2/show/NCT04854291
46. Chen Y, Wu W, Zhao S, Lv X, Hu J, Han C, Wang G, Wang S, Bo P, Zhang J, Gui W, Tang Q, Liu Q, Zhu S, Yu F. Increased Accumulation of α-Synuclein in Inflamed Appendices of Parkinson’s Disease Patients. Mov Disord. 2021 Apr 20. doi: 10.1002/mds.28553.
47. Merk T, Peterson V, Lipski W, BlankertzB, Turner RS, Li N, Horn A, Kuhn A, Richardson RM, Neumann W-J. Electrocorticography is superior to subthalamic local field potentials for movement decoding in Parkinson’s disease. bioRxiv doi: https://doi.org/10.1101/2021.04.24.441207
48. Price DL, Koike MA, Khan A, Wrasidlo W, Rockenstein E, Masliah E, Bonhaus D. The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson’s disease. Sci Rep. 2018 Nov 1;8(1):16165.
49. Mir R, Tonelli F, Lis P, Macartney T, Polinski NK, Martinez TN, Chou MY, Howden AJM, König T, Hotzy C, Milenkovic I, Brücke T, Zimprich A, Sammler E, Alessi DR. The Parkinson’s disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human. Biochem J. 2018 Jun 6;475(11):1861-1883.
50. https://www.anavex.com/anavex-life-sciences-announces-anavex2-73-blarcamesine-improved-both-primary-cognitive-and-secondary-mds-updrs-efficacy-endpoints-with-significant-biomarker-correlation-in-placebo-controlled-p/
51. Metcalfe-Roach A, Yu AC, Golz E, Cirstea M, Sundvick K, Kliger D, Foulger LH, Mackenzie M, Finlay BB, Appel-Cresswell S. MIND and Mediterranean Diets Associated with Later Onset of Parkinson’s Disease. Mov Disord. 2021 Apr;36(4):977-984.
52. Sofi F, Cesari F, Abbate R, Gensini GF, Casini A. Adherence to Mediterranean diet and health status: meta‐analysis. BMJ2008;337:a1344–a1344.
53. Agarwal P, Wang Y, Buchman AS, Holland TM, Bennett DA, Morris MC. MIND diet associated with reduced incidence and delayed progression of parkinsonism in old age.J Nutr Health Aging 2018;22:1211–1215.
54. Kaplan H, Thompson RC, Trumble BC, Wann LS, Allam AH, Beheim B, Frohlich B, Sutherland ML, Sutherland JD, Stieglitz J, Rodriguez DE, Michalik DE, Rowan CJ, Lombardi GP, Bedi R, Garcia AR, Min JK, Narula J, Finch CE, Gurven M, Thomas GS. Coronary atherosclerosis in indigenous South American Tsimane: a cross-sectional cohort study. 2017 Apr 29;389(10080):1730-1739.
55. Irimia A, Chaudhari NN, Robles DJ, Rostowsky KA, Maher AS. The indigenous South American Tsimane exhibit relatively modest decrease in brain volume with age despite high systemic inflammation J Gerontology Series A, https://doi.org/10/1093/gerona/glab138
56. Petrou M, Bohnen NI, Müller ML, Koeppe RA, Albin RL, Frey KA. Aβ-amyloid deposition in patients with Parkinson disease at risk for development of dementia. 2012 Sep 11;79(11):1161-7.
57. Sabbagh MN, Adler CH, Lahti TJ, Connor DJ, Vedders L, Peterson LK, Caviness JN, Shill HA, Sue LI, Ziabreva I, Perry E, Ballard CG, Aarsland D, Walker DG, Beach TG. Parkinson disease with dementia: comparing patients with and without Alzheimer pathology. Alzheimer Dis Assoc Disord. 2009 Jul-Sep;23(3):295-7.
58. Leverenz J, Sumi SM. Parkinson’s disease in patients with Alzheimer’s disease. Arch Neurol. 1986 Jul;43(7):662-4.
59. Hamilton RL. Lewy bodies in Alzheimer’s disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol. 2000 Jul;10(3):378-84.
60. Dai Q, Borenstein AR, Wu Y, Jackson JC, Larson EB. Fruit and vegetable juices and Alzheimer’s disease: the Kame Project. Am J Med. 2006 Sep;119(9):751-9.
61. Ran LS, Liu WH, Fang YY, Xu SB, Li J, Luo X, Pan DJ, Wang MH, Wang W. Alcohol, coffee and tea intake and the risk of cognitive deficits: a dose-response meta-analysis. Epidemiol Psychiatr Sci. 2021 Feb 11;30:e13.
62. Shishtar E, Rogers GT, Blumberg JB, Au R, Jacques PF. Long-term dietary flavonoid intake and risk of Alzheimer disease and related dementias in the Framingham Offspring Cohort. Am J Clin Nutr. 2020 Aug 1;112(2):343-353.
63. Shishtar E, Rogers GT, Blumberg JB, Au R, DeCarli C, Jacques PF. Flavonoid Intake and MRI Markers of Brain Health in the Framingham Offspring Cohort. J Nutr. 2020 Jun 1;150(6):1545-1553.
64. van den Brink AC, Brouwer-Brolsma EM, Berendsen AAM, van de Rest O. The Mediterranean, Dietary Approaches to Stop Hypertension (DASH), and Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) Diets Are Associated with Less Cognitive Decline and a Lower Risk of Alzheimer’s Disease-A Review. Adv Nutr. 2019 Nov 1;10(6):1040-1065.
65. Freyssin A, Page G, Fauconneau B, Rioux Bilan A. Natural polyphenols effects on protein aggregates in Alzheimer’s and Parkinson’s prion-like diseases. Neural Regen Res. 2018 Jun;13(6):955-961.
66. Classen JB. COVID-19 RNA Based Vaccines and the Risk of Prion Disease. Microbiol Infect Dis. 2021; 5(1): 1-3.
67. Bredesen DE, Amos EC, Canick J, Ackerley M, Raji C, Fiala M, Ahdidan J. Reversal of cognitive decline in Alzheimer’s disease. Aging (Albany NY). 2016 Jun;8(6):1250-8.
68. Toups K, Hathaway A, Gordon D, Chung H, Raji C, Boyd A, Hill BD, Hausman-Cohen S, Attarha M, Chwa WJ, Jarrett M, Bredesen DE. Precision Medicine Approach to Alzheimer’s Disease: Successful Proof-of-Concept Trial. https://www.medrxiv.org/content/10.1101/2021.05.10.21256982v1.full-text
69. Soininen H, Solomon A, Visser PJ, Hendrix SB, Blennow K, Kivipelto M, Hartmann T. LipiDiDiet clinical study group. 24-month intervention with a specific multinutrient in people with prodromal Alzheimer’s disease (LipiDiDiet): a randomised, double-blind, controlled trial. Lancet Neurol. 2017 Dec;16(12):965-975.
70. Jacka FN, Cherbuin N, Anstey KJ, Sachdev P, Butterworth P. Western diet is associated with a smaller hippocampus: a longitudinal investigation. BMC Med. 2015 Sep 8;13:215.
71. Richardson K, Fox C, Maidment I, Steel N, Loke YK, Arthur A, Myint PK, Grossi CM, Mattishent K, Bennett K, Campbell NL, Boustani M, Robinson L, Brayne C, Matthews FE, Savva GM. Anticholinergic drugs and risk of dementia: case-control study. 2018 Apr 25;361:k1315.
72. Coupland CAC, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox J. Anticholinergic Drug Exposure and the Risk of Dementia: A Nested Case-Control Study. JAMA Intern Med. 2019 Aug 1;179(8):1084-1093.
73. Alexander GC, Emerson S, Kesselheim AS. Evaluation of Aducanumab for Alzheimer Disease: Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility. 2021;325(17):1717–1718.
74. Knopman DS, Jones DT, Greicius MD. Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019. Alzheimers Dement. 2021 Apr;17(4):696-701.
75. https://www.nytimes.com/2021/06/10/health/aduhelm-fda-resign-alzheimers.html#:~:text=Three%20F.D.A.-,Advisers%20Resign%20Over%20Agency’s%20Approval%20of%20Alzheimer’s%20Drug,evidence%20that%20it%20helps%20patients.&text=%E2%80%9CThis%20might%20be%20the%20worst%20approval%20decision%20that%20the%20F.D.A.,-has%20made%20that
76. Salloway S, Farlow M, McDade E, Clifford DB, Wang G, Llibre-Guerra JJ, Hitchcock JM, Mills SL, Santacruz AM, Aschenbrenner AJ, Hassenstab J, Benzinger TLS, Gordon BA, Fagan AM, Coalier KA, Cruchaga C, Goate AA, Perrin RJ, Xiong C, Li Y, Morris JC, Snider BJ, Mummery C, Surti GM, Hannequin D, Wallon D, Berman SB, Lah JJ, Jimenez-Velazquez IZ, Roberson ED, van Dyck CH, Honig LS, Sánchez-Valle R, Brooks WS, Gauthier S, Galasko DR, Masters CL, Brosch JR, Hsiung GR, Jayadev S, Formaglio M, Masellis M, Clarnette R, Pariente J, Dubois B, Pasquier F, Jack CR Jr, Koeppe R, Snyder PJ, Aisen PS, Thomas RG, Berry SM, Wendelberger BA, Andersen SW, Holdridge KC, Mintun MA, Yaari R, Sims JR, Baudler M, Delmar P, Doody RS, Fontoura P, Giacobino C, Kerchner GA, Bateman RJ; Dominantly Inherited Alzheimer Network–Trials Unit. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease. Nat Med. 2021 Jun 21. doi: 10.1038/s41591-021-01369-8. Epub ahead of print.